Drugs / G-CSF
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02933333 | Sep 2016 → Aug 2020 | acute lymphoblastic leukemia, acute myeloid leukemia, hepatoblastoma, neuroblastoma +1 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02933333 ↗ |
| Modality | Protein / enzyme biologic | “G-CSF is a hematopoietic CSFs” NCT02933333 ↗ |
| Route | Subcutaneous | “received subcutaneous G-CSF 5 μg/kg per day” NCT02933333 ↗ |